Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


London's got Chemistry (biology and physics too)

24 May 2013

With the development of two new £1 billion research parks and a host of world class superboffins working here, the capital is at the nucleus of a serious science explosion.  Joshi Herrmann distils the data.

Professor Stephen Caddick, Vice-Provost (Enterprise) comments.

Read the full London Evening Standard article